Skip to main content
. 2010 May 13;4:97–103. doi: 10.2147/ppa.s9949

Table 2.

HAART composition for HIV–HCV patients starting treatment

Male (n = 144) Female (n = 39)
Protease inhibitor-based HAART 69% (n = 100) 77% (n = 30)
Ritonavir 70% 47%
High-dose ritonavir 39% 30%
Saquinavir 41% 40%
Indinavir 14% 20%
Nelfinavir 17% 23%
Kaletra 23% 7%
Atazanavir 0% 10%
NNRTI-based HAART 22% (n = 31) 18% (n = 7)
Efavirenz 77% 71%
Nucleoside-sparing 10% 0%

Abbreviations: HAART, highly-active antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitors.